Skip to content

Intellia Therapeutics

US · NTLA #2899 by market cap Listed 2016
10.00 +0.48 +5.04%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $27
    Market Newswire · 2026/11/7
  • Company notice
    Intellia Therapeutics | 8-K: Current report
    SEC · 2026/11/13
  • BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $16
    Market Newswire · 2026/11/14
  • Rating change
    Wells Fargo Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)
    TipRanks · 2026/10/5
  • Rating change
    Barclays Initiates Coverage On Intellia Therapeutics With Underweight Rating, Announces Price Target of $8
    Benzinga · 2026/10/6
  • H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/11/13
  • CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49
    Market Newswire · 2026/11/9
  • Rating change
    Wells Fargo Initiates Intellia Therapeutics(NTLA.US) With Hold Rating, Announces Target Price $15
    Market Newswire · 2026/10/15
  • Company notice
    Intellia Therapeutics | 8-K: Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
    SEC · 2026/11/5
  • Company notice
    Intellia Therapeutics | 8-K/A: Current report (Amendment)
    SEC · 2026/11/14
  • J.P. Morgan Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Raises Target Price to $9
    Market Newswire · 2026/11/9
  • Rating change
    Intellia Therapeutics Price Target Announced at $8.00/Share by Barclays
    Dow Jones · 2026/10/7
  • Company notice
    Intellia Therapeutics | 10-Q: Quarterly report
    SEC · 2026/11/6
  • Rating change
    Wells Fargo Keeps Their Hold Rating on Intellia Therapeutics (NTLA)
    TipRanks · 2026/10/15
  • Rating change
    Intellia Therapeutics Initiated at Underweight by Barclays
    Dow Jones · 2026/10/6
  • Rating change
    Barclays Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $8
    Market Newswire · 2026/10/7
  • Rating change
    Barclays Initiates Intellia Therapeutics(NTLA.US) With Sell Rating, Announces Target Price $8
    Market Newswire · 2026/10/6
  • Rating change
    Wedbush Initiates Intellia Therapeutics(NTLA.US) With Hold Rating, Announces Target Price $13
    Market Newswire · 2026/9/9
  • Company notice
    Intellia Therapeutics | SCHEDULE 13G: Others
    SEC · 2026/11/10
  • Rating change
    Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target
    MT Newswires · 2026/10/6
  • Rating change
    Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
    Benzinga · 2026/9/9
  • Rating change
    H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/9/9
  • Company notice
    Intellia Therapeutics | 8-K: Current report
    SEC · 2026/9/9
  • Company notice
    Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/10/6
  • Company notice
    Intellia Therapeutics | 3: Initial statement of beneficial ownership of securities- Marantz Jing L.
    SEC · 2026/10/29

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:29 · For reference only, not investment advice and not tailored to your situation.

Intellia Therapeutics discussion 0 comments

Add a comment